Perspectives on metals-based radioimmunotherapy (RIT): moving forward

Radioimmunotherapy (RIT) is FDA-approved for the clinical management of liquid malignancies, however, its use for solid malignancies remains a challenge. The putative benefit of RIT lies in selective targeting of antigens expressed on the tumor surface using monoclonal antibodies, to systemically de...

Descripción completa

Detalles Bibliográficos
Autores principales: White, Jordan M., Escorcia, Freddy E., Viola, Nerissa T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120204/
https://www.ncbi.nlm.nih.gov/pubmed/33995659
http://dx.doi.org/10.7150/thno.57177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120204/
https://www.ncbi.nlm.nih.gov/pubmed/33995659
http://dx.doi.org/10.7150/thno.57177

Ejemplares similares